Outcomes after resumption of immune checkpoint inhibitor therapy after high‐grade immune‐mediated hepatitis
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Background: In the current study, the authors assessed the risks and outcomes of immune checkpoint inhibitor (ICI) rechallenge in patients with resolved grade 3 to 4 ICI hepatitis because current guidelines recommend permanent ICI discontinuation in these patients. Methods: The authors performed a retrospective cohort study from 2010 through 2019 of patients with melanoma who were treated with ≥1 ICIs and who recovered from grade 3 to 4 ICI hepatitis. The primary outcome was hepatitis recurrence and the secondary outcome was the development of any immune‐related adverse event (irAE) requiring the discontinuation of ICI rechallenge. Best overall response and time to all‐cause death were compared between the patients who did and those who did not undergo ICI rechallenge. Grading was performed using the National Cancer Institute Common Terminology Criteria for Adverse Events (version 5.0). Results: Of the 102 patients with melanoma who developed high‐grade ICI hepatitis, 31 underwent ICI rechallenge. Although 15 of 31 patients (48%) developed an irAE of any grade, only 6 patients (19%) required ICI discontinuation due to irAE severity (4 of 29 patients [14%] rechallenged with anti–PD‐1 or anti‐PD‐L1 and 2 of 2 patients [100%] rechallenged with ipilimumab). Recurrent hepatitis accounted for 4 of these 6 cases. Rechallenged patients who did not require ICI discontinuation were found to be significantly less likely to receive ipilimumab rather than anti–PD‐1 or anti‐PD‐L1 monotherapy (0% vs 33%; relative risk (RR), 0.1 [95% CI, 0.1‐0.3; P = .032]) and significantly less likely to be rechallenged with their original ICI (8% vs 50%; RR, 0.2 [95% CI, 0.1‐0.7; P = .038]). There was no difference noted with regard to best overall response or time to death between rechallenged and non‐rechallenged patients. Conclusions: ICI therapy can be resumed in patients with melanoma who have recovered from grade 3 to 4 ICI hepatitis with a modest risk of serious irAEs. It remains unclear whether ICI retreatment improves clinical outcomes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
Motzer, R. J., Tannir, N. M., McDermott, D. F., Arén Frontera, O., Melichar, B., Choueiri, T. K., Plimack, E. R., Barthélémy, P., Porta, C., George, S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1712126 · Cited by 4,656 · cited 1×
“There is ample evidence that patients with metastatic melanoma have improved survival when treated with combined CTLA-4 and PD-1 inhibition versus single-agent anti–CTLA-4 therapy,(6-8) and combination therapy also has been shown to be beneficial in patients with renal cell carcinoma and hepatocellular carcinoma.(9,10…”
BackgroundFive-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J.-J., Rutkowski, P., Lao, C. D., Cowey, C. L., Schadendorf, D., Wagstaff, J., Dummer, R., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1910836 · Cited by 3,723
Self-citationBrahmer, J. R., Lacchetti, C., Schneider, B. J., Atkins, M. B., Brassil, K. J., Caterino, J. M., Chau, I., Ernstoff, M. S., Gardner, J. M., Ginex, P., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.77.6385 · Cited by 3,713
Haanen, J. B. A. G., Carbonnel, F., Robert, C., Kerr, K. M., Peters, S., Larkin, J., & Jordan, K. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx225 · Cited by 2,367
Immune-related adverse events with immune checkpoint blockade: a comprehensive review
Michot, J. M., Bigenwald, C., Champiat, S., Collins, M., Carbonnel, F., Postel-Vinay, S., Berdelou, A., Varga, A., Bahleda, R., Hollebecque, A., et al. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2015.11.016 · Cited by 2,127 · cited 2×
“Although immune-related adverse events (irAEs) can involve almost any organ system, the most common sites include the gastrointestinal tract, liver, endocrine glands, and skin.(1) Elevated liver enzymes occur in approximately 10% of patients who are treated with single-agent ICI therapy (more commonly with CTLA-4 inhi…”
BackgroundHaanen, J. B. A. G., Carbonnel, F., Robert, C., Kerr, K. M., Peters, S., Larkin, J., & Jordan, K. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy162 · Cited by 431 · cited 2×
“However, the efficacy of dual checkpoint blockade comes at the expense of increased toxicity, with rates of ≥grade 3 hepatitis approaching 15%.(1-3,6,11) Although current guidelines from the American Society of Clinical Oncology and the European Society for Medical Oncology recommend the permanent discontinuation of I…”
BackgroundPollack, M. H., Betof, A., Dearden, H., Rapazzo, K., Valentine, I., Brohl, A. S., Ancell, K. K., Long, G. V., Menzies, A. M., Eroglu, Z., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdx642 · Cited by 393 · cited 2×
“DISCUSSION Although ICIs have had a substantial positive impact on outcomes in patients with advanced malignancies, to our knowledge data regarding the safety and usefulness of ICI rechallenge in patients who previously developed high-grade ICI hepatitis are limited.(12-14) In the current multicenter, retrospective co…”
BackgroundSantini, F. C., Rizvi, H., Plodkowski, A. J., Ni, A., Lacouture, M. E., Gambarin-Gelwan, M., Wilkins, O., Panora, E., Halpenny, D. F., Long, N. M., et al. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0755 · Cited by 331 · cited 2×
“DISCUSSION Although ICIs have had a substantial positive impact on outcomes in patients with advanced malignancies, to our knowledge data regarding the safety and usefulness of ICI rechallenge in patients who previously developed high-grade ICI hepatitis are limited.(12-14) In the current multicenter, retrospective co…”
Background
Cited by
Immune-checkpoint inhibitors: long-term implications of toxicity
Johnson, D. B., Nebhan, C. A., Moslehi, J. J., & Balko, J. M. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00600-w · Cited by 982
Harnessing big data to characterize immune-related adverse events
Jing, Y., Yang, J., Johnson, D. B., Moslehi, J. J., & Han, L. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00597-8 · Cited by 125
Metadata
- Authors
- Li, M., Sack, J. S., Rahma, O. E., Hodi, F. S., Zucker, S. D., & Grover, S.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2020-09-05
- Volume
- 126
- Issue
- 23
- Pages
- 5088-5097
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W3083702883
- Cited by
- 55
- References
- 8
- FWCI
- 2.25
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Outcomes after resumption of immune checkpoint inhibitor therapy after high‐grade immune‐mediated hepatitis. https://app.cochat.ai/papers/10.1002/cncr.33165
- The paper
- Li, M., Sack, J. S., Rahma, O. E., Hodi, F. S., Zucker, S. D., & Grover, S. (2020). Outcomes after resumption of immune checkpoint inhibitor therapy after high‐grade immune‐mediated hepatitis. Cancer. https://doi.org/10.1002/cncr.33165
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.